Evidence map›Paper›PMID 35263737›Full record

ArticleAmerican journal of nephrology2022

Endocannabinoid System in Polycystic Kidney Disease.

Jost Klawitter, Cristina Sempio, Matthew J Jackson, Peter H Smith, Katharina Hopp, Michel Chonchol, Berenice Y Gitomer, Uwe Christians, Jelena Klawitter

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of nephrology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Jost KlawitterDeparment of Anesthesiology, University of Colorado Denver, Denver, Colorado, USA.
Cristina SempioDeparment of Anesthesiology, University of Colorado Denver, Denver, Colorado, USA.
Matthew J JacksonDeparment of Anesthesiology, University of Colorado Denver, Denver, Colorado, USA.
Peter H SmithDeparment of Anesthesiology, University of Colorado Denver, Denver, Colorado, USA.
Katharina HoppDivision of Renal Diseases and Hypertension, University of Colorado School of Medicine, Denver, Colorado, USA.
Michel ChoncholDivision of Renal Diseases and Hypertension, University of Colorado School of Medicine, Denver, Colorado, USA.
Berenice Y GitomerDivision of Renal Diseases and Hypertension, University of Colorado School of Medicine, Denver, Colorado, USA.
Uwe ChristiansDeparment of Anesthesiology, University of Colorado Denver, Denver, Colorado, USA.
Jelena KlawitterDeparment of Anesthesiology, University of Colorado Denver, Denver, Colorado, USA.
University of Colorado Denver · US

Funding

The role of inflammation in the progression of polycystic kidney diseaseR01DK114424 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI GITOMER, BERENICE YOLANDE, KLAWITTER, JELENA · 2018 to 2020
$668k
NIDDK NIH HHS R01 DK114424
6 · The paper itself

Abstract

introductionAutosomal dominant polycystic kidney disease (ADPKD) is a commonly inherited disorder characterized by renal cyst formation. A major pathological feature of ADPKD is the development of interstitial inflammation. The endocannabinoid (EC) system is present in the kidney and has recently emerged as an important player in inflammation and the pathogenesis of progressive kidney disease.

methodsData on ECs were collected using a validated mass spectrometry assay from a well-characterized cohort of 102 ADPKD patients (at baseline and after 2- and 4 years on standard vs. rigorous blood-pressure control) and compared to 100 healthy subjects.

resultsCompared to healthy individuals, we found higher interleukins-6 and -1b as well as reduced plasma levels of anandamide (AEA), 2-arachidonoyl-glycerol (2-AG), and their congeners in ADPKD patients. Baseline AEA concentration negatively associated with the progression of ADPKD as expressed by the yearly percent change in height-corrected total kidney volume and positively with the yearly change in renal function (measured as estimated glomerular filtration rate, ΔeGFR). AEA analog palmitoylethanolamide (PEA) is also associated positively with the yearly change in eGFR. DISCUSSION AND

conclusionThe results of the present study suggest that ADPKD patients present with lower levels of ECs and that reestablishing the normality of the renal EC system via augmentation of AEA, PEA, and 2-AG levels, either through the increase of their synthesis or through a reduction of their degradation, could be beneficial and may present a promising therapeutic target in said patients.

Indexed as

Polycystic Kidney, Autosomal DominantDisease ProgressionEndocannabinoidsFemaleGlomerular Filtration RateHumansInflammationKidneyMaleEndocannabinoids2-ArachidonoylglycerolAnandamideAutosomal dominant polycystic kidney diseaseEndocannabinoids

Identifiers

PMID35263737
PMCPMC9173653
OpenAlexW4221001839

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.